Odetto Diego, Cortez Juan P, Saadi José M, Zamora Liliana B, Riggi María C, Lamm Marina, Perrotta Myriam B
Sección Ginecología Oncológica, Hospital Italiano de Buenos Aires, Argentina. E-mail:
Sección Ginecología Oncológica, Hospital Italiano de Buenos Aires, Argentina.
Medicina (B Aires). 2021;81(4):565-573.
Ovarian cancer represents the third gynecological cancer in frequency in Argentina. There is a lack of information on this pathology in our country regarding the treatment and evolution of patients who suffer it. The aim of this study was to evaluate the perioperative and oncological results in patients with advanced epithelial ovarian tumor. We present a retrospective cohort in which we evaluated disease-free survival and overall survival in patients with epithelial ovarian tumor treated at the Hospital Italiano de Buenos Aires between June 2009 and June 2017. Of 170 patients included in the study, 72 (42.4%) received primary debulking surgery (CCP), while 98 (57.6%) received neoadjuvant therapy and interval surgery (CI). The optimal cyto-reduction rate was 75% and 79% respectively. No differences were found in perioperative outcomes, or in severe complications between the two groups. The median disease-free survival in the CCP group was 2.5 years (95% CI 1.6-3.1) while in the CI group it was 1.4 (95% CI 1.2-1.7) p < 0.001. The median overall survival was 5.8 years in CPP, and 3.5 years in CI. Faced with a meticulous selection by a group of experts, patients with advanced ovarian cancer treated with CCP present better oncological results than those who received neoadjuvant therapy and CI.
卵巢癌是阿根廷发病率第三高的妇科癌症。在我国，关于这种疾病患者的治疗和病情发展缺乏相关信息。本研究的目的是评估晚期上皮性卵巢肿瘤患者的围手术期和肿瘤学结果。我们进行了一项回顾性队列研究，评估了2009年6月至2017年6月期间在布宜诺斯艾利斯意大利医院接受治疗的上皮性卵巢肿瘤患者的无病生存期和总生存期。在纳入研究的170例患者中，72例（42.4%）接受了初次肿瘤细胞减灭术（CCP），而98例（57.6%）接受了新辅助治疗和间隔手术（CI）。最佳肿瘤细胞减灭率分别为75%和79%。两组在围手术期结果或严重并发症方面均未发现差异。CCP组的无病生存期中位数为2.5年（95%CI 1.6 - 3.1），而CI组为1.4年（95%CI 1.2 - 1.7），p < 0.001。CPP组的总生存期中位数为5.8年，CI组为3.5年。在经过一组专家的精心挑选后，接受CCP治疗的晚期卵巢癌患者比接受新辅助治疗和CI的患者呈现出更好的肿瘤学结果。
